Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL

Marker Therapeutics, Inc.

Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).
Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.
Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.
MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.
New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Marker Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $12.2 million.

Period: the year ended December 31, 2025
Net income: $12.2 million
Result: reported results

Exact text from the filing

Marker reported a net loss of $12.2 million for the year ended December 31, 2025

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-031309

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.